-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
SpringWorks Therapeutics (NASDAQ:SWTX) Stock Price Up 3.7%
SpringWorks Therapeutics (NASDAQ:SWTX) Stock Price Up 3.7%
Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Get Rating) rose 3.7% during trading on Friday . The stock traded as high as $28.16 and last traded at $28.16. Approximately 1,048 shares changed hands during mid-day trading, a decline of 100% from the average daily volume of 1,027,558 shares. The stock had previously closed at $27.15.
Analyst Ratings Changes
SWTX has been the subject of several recent research reports. HC Wainwright raised their price target on shares of SpringWorks Therapeutics from $94.00 to $103.00 and gave the company a "buy" rating in a research report on Monday, September 12th. Wedbush set a $53.00 price objective on shares of SpringWorks Therapeutics in a report on Monday, June 20th.
Get SpringWorks Therapeutics alerts:SpringWorks Therapeutics Trading Up 5.1 %
The stock's fifty day moving average price is $28.60 and its two-hundred day moving average price is $34.90. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of -6.12 and a beta of 0.85.
SpringWorks Therapeutics (NASDAQ:SWTX – Get Rating) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($1.41) earnings per share for the quarter, missing analysts' consensus estimates of ($1.26) by ($0.15). During the same quarter last year, the business posted ($0.97) EPS. SpringWorks Therapeutics's revenue was up .0% compared to the same quarter last year. Analysts anticipate that SpringWorks Therapeutics, Inc. will post -5.36 earnings per share for the current fiscal year.Insider Buying and Selling
In related news, major shareholder Orbimed Advisors Llc sold 153,897 shares of SpringWorks Therapeutics stock in a transaction on Monday, September 12th. The shares were sold at an average price of $31.96, for a total transaction of $4,918,548.12. Following the sale, the insider now directly owns 5,599,842 shares in the company, valued at approximately $178,970,950.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 28.95% of the stock is owned by company insiders.
Institutional Investors Weigh In On SpringWorks Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of SWTX. Nisa Investment Advisors LLC increased its stake in SpringWorks Therapeutics by 107.0% in the second quarter. Nisa Investment Advisors LLC now owns 1,780 shares of the company's stock valued at $44,000 after purchasing an additional 920 shares during the period. Assetmark Inc. raised its stake in SpringWorks Therapeutics by 319.7% during the 2nd quarter. Assetmark Inc. now owns 1,813 shares of the company's stock valued at $45,000 after acquiring an additional 1,381 shares during the last quarter. Parallel Advisors LLC lifted its position in SpringWorks Therapeutics by 34.7% during the 1st quarter. Parallel Advisors LLC now owns 1,028 shares of the company's stock worth $61,000 after acquiring an additional 265 shares during the period. Amundi acquired a new stake in SpringWorks Therapeutics during the 2nd quarter worth approximately $77,000. Finally, US Bancorp DE lifted its position in SpringWorks Therapeutics by 20.7% during the 2nd quarter. US Bancorp DE now owns 3,246 shares of the company's stock worth $80,000 after acquiring an additional 556 shares during the period.
About SpringWorks Therapeutics
(Get Rating)
SpringWorks Therapeutics, Inc acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors.
Recommended Stories
- Get a free copy of the StockNews.com research report on SpringWorks Therapeutics (SWTX)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Let Paychex Stock Work Hard For You
- How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Get Rating) rose 3.7% during trading on Friday . The stock traded as high as $28.16 and last traded at $28.16. Approximately 1,048 shares changed hands during mid-day trading, a decline of 100% from the average daily volume of 1,027,558 shares. The stock had previously closed at $27.15.
在周五的交易中,SpringWorks治疗公司(纳斯达克代码:SWTX-GET评级)的股价上涨了3.7%。该股一度涨至28.16美元,最后报28.16美元。午盘交易中,约有1,048股易手,较1,027,558股的日均成交量下降了100%。该股此前收盘价为27.15美元。
Analyst Ratings Changes
分析师评级发生变化
SWTX has been the subject of several recent research reports. HC Wainwright raised their price target on shares of SpringWorks Therapeutics from $94.00 to $103.00 and gave the company a "buy" rating in a research report on Monday, September 12th. Wedbush set a $53.00 price objective on shares of SpringWorks Therapeutics in a report on Monday, June 20th.
SWTX是最近几份研究报告的主题。9月12日,周一,在一份研究报告中,HC Wainwright将SpringWorks Treateutics的股票目标价从94美元上调至103.00美元,并给予该公司“买入”评级。韦德布什在6月20日星期一的一份报告中为SpringWorks治疗公司的股票设定了53.00美元的目标价。
SpringWorks Therapeutics Trading Up 5.1 %
SpringWorks治疗公司股价上涨5.1%
The stock's fifty day moving average price is $28.60 and its two-hundred day moving average price is $34.90. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of -6.12 and a beta of 0.85.
该股的50日移动均线价格为28.60美元,200日移动均线价格为34.90美元。该公司的市值为17.8亿美元,市盈率为-6.12倍,贝塔系数为0.85。
Insider Buying and Selling
内幕买卖
In related news, major shareholder Orbimed Advisors Llc sold 153,897 shares of SpringWorks Therapeutics stock in a transaction on Monday, September 12th. The shares were sold at an average price of $31.96, for a total transaction of $4,918,548.12. Following the sale, the insider now directly owns 5,599,842 shares in the company, valued at approximately $178,970,950.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 28.95% of the stock is owned by company insiders.
相关新闻,大股东Orbimed Advisors LLC在9月12日(星期一)的一笔交易中出售了153,897股SpringWorks治疗公司的股票。这些股票的平均价格为31.96美元,总成交金额为4918,548.12美元。出售后,这位内部人士现在直接拥有该公司5,599,842股,价值约178,970,950.32美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过此超链接。28.95%的股份由公司内部人士持有。
Institutional Investors Weigh In On SpringWorks Therapeutics
机构投资者看好SpringWorks治疗公司
Several hedge funds and other institutional investors have recently bought and sold shares of SWTX. Nisa Investment Advisors LLC increased its stake in SpringWorks Therapeutics by 107.0% in the second quarter. Nisa Investment Advisors LLC now owns 1,780 shares of the company's stock valued at $44,000 after purchasing an additional 920 shares during the period. Assetmark Inc. raised its stake in SpringWorks Therapeutics by 319.7% during the 2nd quarter. Assetmark Inc. now owns 1,813 shares of the company's stock valued at $45,000 after acquiring an additional 1,381 shares during the last quarter. Parallel Advisors LLC lifted its position in SpringWorks Therapeutics by 34.7% during the 1st quarter. Parallel Advisors LLC now owns 1,028 shares of the company's stock worth $61,000 after acquiring an additional 265 shares during the period. Amundi acquired a new stake in SpringWorks Therapeutics during the 2nd quarter worth approximately $77,000. Finally, US Bancorp DE lifted its position in SpringWorks Therapeutics by 20.7% during the 2nd quarter. US Bancorp DE now owns 3,246 shares of the company's stock worth $80,000 after acquiring an additional 556 shares during the period.
几家对冲基金和其他机构投资者最近买卖了SWTX的股票。NISA Investment Advisors LLC在第二季度增持了SpringWorks Treateutics的股份107.0%。NISA Investment Advisors LLC在此期间又购买了920股,现在拥有1,780股该公司的股票,价值44,000美元。AssetMark Inc.在第二季度将其在SpringWorks Treateutics的持股增加了319.7%。AssetMark Inc.在上个季度增持了1,381股后,现在持有1,813股该公司股票,价值45,000美元。平行顾问公司在第一季度将其在SpringWorks Treateutics的地位提高了34.7%。Parly Advisors LLC在此期间额外收购了265股,现在拥有1,028股该公司股票,价值61,000美元。Amundi在第二季度收购了SpringWorks Treeutics的新股份,价值约7.7万美元。最后,US Bancorp DE在第二季度将其在SpringWorks Treateutics的头寸提高了20.7%。US Bancorp DE现在拥有3246股该公司股票,价值8万美元,在此期间又购买了556股。
About SpringWorks Therapeutics
关于SpringWorks治疗公司
(Get Rating)
(获取评级)
SpringWorks Therapeutics, Inc acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors.
SpringWorks治疗公司为患有罕见疾病和癌症的未得到充分服务的患者群体收购、开发和商业化药物。它的主要候选产品是Niroacestat,一种口服小分子伽马分泌酶抑制剂,正在进行治疗韧带样肿瘤的第三阶段临床试验。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on SpringWorks Therapeutics (SWTX)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Let Paychex Stock Work Hard For You
- How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
- 免费获取StockNews.com关于SpringWorks治疗公司(SWTX)的研究报告
- 电动汽车电池制造商Freyr将在全球大举扩张
- MarketBeat:回顾一周9/26-9/30
- 这是买入美光科技的难忘时刻
- 让Paychex股票为您努力工作
- Keurig Dr Pepper与规模更大的竞争对手可口可乐(Coke&Pepsi)相比如何?
Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
获得SpringWorks治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对SpringWorks Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧